{"id": "article-21731_0", "title": "Fibrocystic Breast Disease -- Continuing Education Activity", "content": "Fibrocystic breast disease is the most common benign type of breast disease, diagnosed in millions of women worldwide. Certain hormonal factors underpin the function, evaluation, and treatment of this disease. Benign breast disease is an umbrella term for various non-malignant lesions, such as tumors, trauma, mastalgia, and nipple discharge. This activity reviews the indications, symptomology, management, and other key elements related to fibrocystic breast disease in the clinical setting related to the essential points needed by members of an interprofessional team managing the care of patients with the condition and sequelae.", "contents": "Fibrocystic Breast Disease -- Continuing Education Activity. Fibrocystic breast disease is the most common benign type of breast disease, diagnosed in millions of women worldwide. Certain hormonal factors underpin the function, evaluation, and treatment of this disease. Benign breast disease is an umbrella term for various non-malignant lesions, such as tumors, trauma, mastalgia, and nipple discharge. This activity reviews the indications, symptomology, management, and other key elements related to fibrocystic breast disease in the clinical setting related to the essential points needed by members of an interprofessional team managing the care of patients with the condition and sequelae."}
{"id": "article-21731_1", "title": "Fibrocystic Breast Disease -- Continuing Education Activity", "content": "Objectives: Summarize the pathophysiology of fibrocystic breast conditions. Outline the appropriate history, physical, and evaluation of a patient presenting with symptoms associated with benign breast disease. Review the treatment and management options available for fibrocystic breast disease. Describe some interprofessional team strategies for improving care coordination and communication to advance patient education regarding this disease and improve outcomes. Access free multiple choice questions on this topic.", "contents": "Fibrocystic Breast Disease -- Continuing Education Activity. Objectives: Summarize the pathophysiology of fibrocystic breast conditions. Outline the appropriate history, physical, and evaluation of a patient presenting with symptoms associated with benign breast disease. Review the treatment and management options available for fibrocystic breast disease. Describe some interprofessional team strategies for improving care coordination and communication to advance patient education regarding this disease and improve outcomes. Access free multiple choice questions on this topic."}
{"id": "article-21731_2", "title": "Fibrocystic Breast Disease -- Introduction", "content": "Fibrocystic breast disease is the most common benign type of breast disease, diagnosed in millions of women worldwide. Certain hormonal factors underpin the function, evaluation, and treatment of this disease. Benign breast disease is an umbrella term for various non-malignant lesions, such as\u00a0tumors, trauma, mastalgia, and nipple discharge. [1]", "contents": "Fibrocystic Breast Disease -- Introduction. Fibrocystic breast disease is the most common benign type of breast disease, diagnosed in millions of women worldwide. Certain hormonal factors underpin the function, evaluation, and treatment of this disease. Benign breast disease is an umbrella term for various non-malignant lesions, such as\u00a0tumors, trauma, mastalgia, and nipple discharge. [1]"}
{"id": "article-21731_3", "title": "Fibrocystic Breast Disease -- Introduction", "content": "The above-mentioned\u00a0benign lesions\u00a0are not associated with an increased risk for\u00a0malignancy; however, it associates with an up to 50% risk of developing breast cancer under certain histopathological and clinical circumstances. [2] A palpable mass upon clinical evaluation is evident in both benign and malignant breast conditions. The clinical findings include symptoms such as\u00a0dimpling of the skin (peau d'orange), thickening,\u00a0pain, and nipple discharge. [3] The most common investigative tools to assess for these clinical findings are\u00a0mammograms and ultrasound. [4]", "contents": "Fibrocystic Breast Disease -- Introduction. The above-mentioned\u00a0benign lesions\u00a0are not associated with an increased risk for\u00a0malignancy; however, it associates with an up to 50% risk of developing breast cancer under certain histopathological and clinical circumstances. [2] A palpable mass upon clinical evaluation is evident in both benign and malignant breast conditions. The clinical findings include symptoms such as\u00a0dimpling of the skin (peau d'orange), thickening,\u00a0pain, and nipple discharge. [3] The most common investigative tools to assess for these clinical findings are\u00a0mammograms and ultrasound. [4]"}
{"id": "article-21731_4", "title": "Fibrocystic Breast Disease -- Introduction", "content": "The\u00a0main components of the breast are prone to fibrocystic changes during hormonal fluctuations. These components include the stroma, ducts, and lobules of the breast.\u00a0During the reproductive age, glandular breast tissue has a direct relation to cyclical surges\u00a0of plasma levels of estradiol and progesterone. [1]", "contents": "Fibrocystic Breast Disease -- Introduction. The\u00a0main components of the breast are prone to fibrocystic changes during hormonal fluctuations. These components include the stroma, ducts, and lobules of the breast.\u00a0During the reproductive age, glandular breast tissue has a direct relation to cyclical surges\u00a0of plasma levels of estradiol and progesterone. [1]"}
{"id": "article-21731_5", "title": "Fibrocystic Breast Disease -- Etiology", "content": "The etiology of benign breast disease has demonstrated a strong clinical association with women receiving estrogen and anti-estrogen treatment. The prevalence of benign breast lesions in postmenopausal women receiving estrogens and progestins for over eight years is increased by 1.7 fold. During the Women\u2019s Health Initiative study (WHI), the combined use of estrogen and progestin correlated with a 74% risk of benign breast disease. The use of anti-estrogens led to a\u00a028% reduction in the prevalence of benign proliferative breast disease. [5]", "contents": "Fibrocystic Breast Disease -- Etiology. The etiology of benign breast disease has demonstrated a strong clinical association with women receiving estrogen and anti-estrogen treatment. The prevalence of benign breast lesions in postmenopausal women receiving estrogens and progestins for over eight years is increased by 1.7 fold. During the Women\u2019s Health Initiative study (WHI), the combined use of estrogen and progestin correlated with a 74% risk of benign breast disease. The use of anti-estrogens led to a\u00a028% reduction in the prevalence of benign proliferative breast disease. [5]"}
{"id": "article-21731_6", "title": "Fibrocystic Breast Disease -- Etiology -- Study selection criteria", "content": "The analysis used prospective cohort\u00a0and\u00a0nested case-control studies of at least 300 cases and\u00a0meta-analyses.", "contents": "Fibrocystic Breast Disease -- Etiology -- Study selection criteria. The analysis used prospective cohort\u00a0and\u00a0nested case-control studies of at least 300 cases and\u00a0meta-analyses."}
{"id": "article-21731_7", "title": "Fibrocystic Breast Disease -- Etiology -- See Table 1", "content": "* Relative risks estimated from standardized incidence ratios. \u2020 Controls were women who had non-proliferative benign breast disease. [2] Polycystic ovary syndrome (PCOS) typically presents with factors such as anovulation and hyperandrogenaemia, which is evident in\u00a05 to10% of women within reproductive age. [6]", "contents": "Fibrocystic Breast Disease -- Etiology -- See Table 1. * Relative risks estimated from standardized incidence ratios. \u2020 Controls were women who had non-proliferative benign breast disease. [2] Polycystic ovary syndrome (PCOS) typically presents with factors such as anovulation and hyperandrogenaemia, which is evident in\u00a05 to10% of women within reproductive age. [6]"}
{"id": "article-21731_8", "title": "Fibrocystic Breast Disease -- Etiology -- See Table 1", "content": "Previous studies have concluded that\u00a0hyperestrogenism and anovulation are associated with\u00a0benign breast conditions, as the growth of glandular breast tissue is affected by the levels of estrogen and progesterone in pathological processes. [7]", "contents": "Fibrocystic Breast Disease -- Etiology -- See Table 1. Previous studies have concluded that\u00a0hyperestrogenism and anovulation are associated with\u00a0benign breast conditions, as the growth of glandular breast tissue is affected by the levels of estrogen and progesterone in pathological processes. [7]"}
{"id": "article-21731_9", "title": "Fibrocystic Breast Disease -- Epidemiology", "content": "There is varied literature, ranging from 30\u00a0to 60% of all women. It is most common in women between the ages of 30\u00a0to 50 years. [8]", "contents": "Fibrocystic Breast Disease -- Epidemiology. There is varied literature, ranging from 30\u00a0to 60% of all women. It is most common in women between the ages of 30\u00a0to 50 years. [8]"}
{"id": "article-21731_10", "title": "Fibrocystic Breast Disease -- Epidemiology", "content": "One of the most common forms of benign breast disease is fibroadenomas, characterized by localized proliferation of breast ducts and stroma.\u00a0This subtype\u00a0accounts for 70 to 95% of all tumor benign type of breast disease. The incidence is\u00a0mostly seen in the 17 to 20 year age group,\u00a0extending to 2 years premenarche at 35. [3]", "contents": "Fibrocystic Breast Disease -- Epidemiology. One of the most common forms of benign breast disease is fibroadenomas, characterized by localized proliferation of breast ducts and stroma.\u00a0This subtype\u00a0accounts for 70 to 95% of all tumor benign type of breast disease. The incidence is\u00a0mostly seen in the 17 to 20 year age group,\u00a0extending to 2 years premenarche at 35. [3]"}
{"id": "article-21731_11", "title": "Fibrocystic Breast Disease -- Pathophysiology", "content": "Mammary gland development, maturation, and differentiation act upon the hormonal and growth factor changes affecting the stromal and epithelial cells. [4]", "contents": "Fibrocystic Breast Disease -- Pathophysiology. Mammary gland development, maturation, and differentiation act upon the hormonal and growth factor changes affecting the stromal and epithelial cells. [4]"}
{"id": "article-21731_12", "title": "Fibrocystic Breast Disease -- Pathophysiology", "content": "During the late proliferative phase, glandular tissue evolves to hyperplastic stages such as sclerosing adenosis or lobular hyperplasia. This state of hyperplasia, if associated with a 2% prevalence of Ki67 cells, has a twofold increased incidence for the development of breast cancer. [9] Various types of benign breast disease exist, such as hyperplasia, cysts, fibroadenomas, sclerosing adenosis, and mastitis.", "contents": "Fibrocystic Breast Disease -- Pathophysiology. During the late proliferative phase, glandular tissue evolves to hyperplastic stages such as sclerosing adenosis or lobular hyperplasia. This state of hyperplasia, if associated with a 2% prevalence of Ki67 cells, has a twofold increased incidence for the development of breast cancer. [9] Various types of benign breast disease exist, such as hyperplasia, cysts, fibroadenomas, sclerosing adenosis, and mastitis."}
{"id": "article-21731_13", "title": "Fibrocystic Breast Disease -- Histopathology", "content": "There is a limited pathological consensus regarding the histopathological appearance of benign breast disease. The main features are an\u00a0extracellular matrix of collagen, peri canalicular patterns of stromal cells with the presence of florid epithelial hyperplasia. During the menopausal phase, fibroadenomas involute, which affects\u00a0dense collagen stroma and atrophic glands. [10]", "contents": "Fibrocystic Breast Disease -- Histopathology. There is a limited pathological consensus regarding the histopathological appearance of benign breast disease. The main features are an\u00a0extracellular matrix of collagen, peri canalicular patterns of stromal cells with the presence of florid epithelial hyperplasia. During the menopausal phase, fibroadenomas involute, which affects\u00a0dense collagen stroma and atrophic glands. [10]"}
{"id": "article-21731_14", "title": "Fibrocystic Breast Disease -- Histopathology", "content": "Cystic changes derive from the terminal duct lobular unit (TDLU). Due to the expansion of the efferent ductules of the TDLU, cysts form as a result of fluid accumulation in these structures. The lining appears flat with a myoepithelial layer present. [5]", "contents": "Fibrocystic Breast Disease -- Histopathology. Cystic changes derive from the terminal duct lobular unit (TDLU). Due to the expansion of the efferent ductules of the TDLU, cysts form as a result of fluid accumulation in these structures. The lining appears flat with a myoepithelial layer present. [5]"}
{"id": "article-21731_15", "title": "Fibrocystic Breast Disease -- Histopathology -- Image 3", "content": "Microscopic histology section of fibroadenosis", "contents": "Fibrocystic Breast Disease -- Histopathology -- Image 3. Microscopic histology section of fibroadenosis"}
{"id": "article-21731_16", "title": "Fibrocystic Breast Disease -- History and Physical", "content": "Benign cysts are typically mobile within the glandular breast tissue, chest wall, and skin and are rubber-like in texture. Except for inflammatory type cysts, discomfort and tenderness experienced by a patient are either absent or mild. Most patients present with multiple cysts upon further clinical and diagnostic evaluation. [11]", "contents": "Fibrocystic Breast Disease -- History and Physical. Benign cysts are typically mobile within the glandular breast tissue, chest wall, and skin and are rubber-like in texture. Except for inflammatory type cysts, discomfort and tenderness experienced by a patient are either absent or mild. Most patients present with multiple cysts upon further clinical and diagnostic evaluation. [11]"}
{"id": "article-21731_17", "title": "Fibrocystic Breast Disease -- History and Physical", "content": "Various subtypes of cysts are known, including hyperplastic fibrous cysts, adenosis, and papillomatosis. These types of cysts are usually found in the upper outer quadrants of the breast, as well as in the central margins. The texture upon evaluation ranges from a firm texture to multiple subcentimeter cysts. [12]", "contents": "Fibrocystic Breast Disease -- History and Physical. Various subtypes of cysts are known, including hyperplastic fibrous cysts, adenosis, and papillomatosis. These types of cysts are usually found in the upper outer quadrants of the breast, as well as in the central margins. The texture upon evaluation ranges from a firm texture to multiple subcentimeter cysts. [12]"}
{"id": "article-21731_18", "title": "Fibrocystic Breast Disease -- History and Physical", "content": "Fibroadenomas present in varied sizes with a common oval-shaped, well-defined margin. As with cysts, fibroadenomas are mobile upon evaluation and are often multiple, occurring either simultaneously or over a specified period. [13] Nipple discharge is associated with\u00a0ductal ectasia, intraductal papilloma, or in rare instances, carcinoma.", "contents": "Fibrocystic Breast Disease -- History and Physical. Fibroadenomas present in varied sizes with a common oval-shaped, well-defined margin. As with cysts, fibroadenomas are mobile upon evaluation and are often multiple, occurring either simultaneously or over a specified period. [13] Nipple discharge is associated with\u00a0ductal ectasia, intraductal papilloma, or in rare instances, carcinoma."}
{"id": "article-21731_19", "title": "Fibrocystic Breast Disease -- History and Physical", "content": "The finding of an intraductal papilloma\u00a0is associated with a single duct presenting a bloody, sudden discharge with a small palpable nodule in the retro areolar region. Multiple ducts presenting with\u00a0nonspontaneous, green, yellow, clear\u00a0discharges are a common feature with\u00a0duct ectasia. [14]", "contents": "Fibrocystic Breast Disease -- History and Physical. The finding of an intraductal papilloma\u00a0is associated with a single duct presenting a bloody, sudden discharge with a small palpable nodule in the retro areolar region. Multiple ducts presenting with\u00a0nonspontaneous, green, yellow, clear\u00a0discharges are a common feature with\u00a0duct ectasia. [14]"}
{"id": "article-21731_20", "title": "Fibrocystic Breast Disease -- Evaluation", "content": "Triple testing is a combination consisting of clinical examination, imaging, and excision\u00a0biopsy. This is essential for all women with a clinical finding, such as a discrete palpable mass.", "contents": "Fibrocystic Breast Disease -- Evaluation. Triple testing is a combination consisting of clinical examination, imaging, and excision\u00a0biopsy. This is essential for all women with a clinical finding, such as a discrete palpable mass."}
{"id": "article-21731_21", "title": "Fibrocystic Breast Disease -- Evaluation", "content": "Nodularity in young women less than 30 years of age may have management with clinical surveillance and short-term follow-up examination in 2\u00a0to 3 months. An investigation may be necessary if the lump has changed on review or if, at the initial presentation, there is a\u00a0new change in her breasts. [15] Nodularity or thickening that is asymmetric in women over the age of 30 years, further investigation utilizing\u00a0mammography and ultrasound, is warranted.", "contents": "Fibrocystic Breast Disease -- Evaluation. Nodularity in young women less than 30 years of age may have management with clinical surveillance and short-term follow-up examination in 2\u00a0to 3 months. An investigation may be necessary if the lump has changed on review or if, at the initial presentation, there is a\u00a0new change in her breasts. [15] Nodularity or thickening that is asymmetric in women over the age of 30 years, further investigation utilizing\u00a0mammography and ultrasound, is warranted."}
{"id": "article-21731_22", "title": "Fibrocystic Breast Disease -- Evaluation", "content": "Short-term\u00a0follow-up is an important part of the management of nodularity so that the progression in size of a\u00a0mass of nodularity or other associated findings (e.g., skin or nipple changes) is detected.", "contents": "Fibrocystic Breast Disease -- Evaluation. Short-term\u00a0follow-up is an important part of the management of nodularity so that the progression in size of a\u00a0mass of nodularity or other associated findings (e.g., skin or nipple changes) is detected."}
{"id": "article-21731_23", "title": "Fibrocystic Breast Disease -- Evaluation", "content": "Mammography with ultrasound examination is required for all\u00a0discrete palpable lesions in women over 35 to distinguish cysts from solid lesions. Complex cysts containing both fluid and solid matter require biopsy. For solid lesions, radiographically or ultrasonically directed core biopsy provides further information regarding the presence or absence of malignancy. Core excision biopsy involves a\u00a0cutting needle with\u00a0a spring-loaded, automated biopsy instrument that allows sufficient specimen of tissue\u00a0for histologic analysis.", "contents": "Fibrocystic Breast Disease -- Evaluation. Mammography with ultrasound examination is required for all\u00a0discrete palpable lesions in women over 35 to distinguish cysts from solid lesions. Complex cysts containing both fluid and solid matter require biopsy. For solid lesions, radiographically or ultrasonically directed core biopsy provides further information regarding the presence or absence of malignancy. Core excision biopsy involves a\u00a0cutting needle with\u00a0a spring-loaded, automated biopsy instrument that allows sufficient specimen of tissue\u00a0for histologic analysis."}
{"id": "article-21731_24", "title": "Fibrocystic Breast Disease -- Evaluation", "content": "FNA allows\u00a0a\u00a0cytopathologist to evaluate cellular material. [16] However, the amount of material retrieved during FNA procedures being sufficient for diagnosis is non-successful in 35 to 47% of non-palpable lesions. A core biopsy is then the recommendation. [17]", "contents": "Fibrocystic Breast Disease -- Evaluation. FNA allows\u00a0a\u00a0cytopathologist to evaluate cellular material. [16] However, the amount of material retrieved during FNA procedures being sufficient for diagnosis is non-successful in 35 to 47% of non-palpable lesions. A core biopsy is then the recommendation. [17]"}
{"id": "article-21731_25", "title": "Fibrocystic Breast Disease -- Evaluation", "content": "Cytology of nipple discharge has limited specificity and sensitivity to\u00a0detect\u00a0malignancy (35\u00a0to 47%). If the results of both clinical and diagnostic evaluations are\u00a0benign, a 6\u00a0to 12-month\u00a0clinical breast examination, ultrasound, and mammography are the suggested follow-up to confirm a stable appearance.", "contents": "Fibrocystic Breast Disease -- Evaluation. Cytology of nipple discharge has limited specificity and sensitivity to\u00a0detect\u00a0malignancy (35\u00a0to 47%). If the results of both clinical and diagnostic evaluations are\u00a0benign, a 6\u00a0to 12-month\u00a0clinical breast examination, ultrasound, and mammography are the suggested follow-up to confirm a stable appearance."}
{"id": "article-21731_26", "title": "Fibrocystic Breast Disease -- Evaluation", "content": "A study of 156 patients in Japan who had a benign breast biopsy showed that 13 percent required a subsequent biopsy within two years of having routine FNA procedures performed. In a retrospective study, 150 patients with benign histology after ultrasound-guided vacuum-assisted biopsy for complex cystic breast lesions (BI-RADS 4) were assessed. This subset of patients underwent study in 6 monthly intervals. Of the 104 lesions, none led to the development of malignancy. [4] Routine ultrasound screening in\u00a0Japan was used with\u00a010519 women to evaluate recall criteria.\u00a0Researchers noted a cystic-type breast pattern in 6512 cases. Only one of the patient cases reported malignancy the following year, related to a solid tumor with a cystic component, proven to be a micro-invasive cancer of less than 1 mm. There was no cancer diagnosed in this subset of patients. Most of the study subjects were less than 40 years of age. [18]", "contents": "Fibrocystic Breast Disease -- Evaluation. A study of 156 patients in Japan who had a benign breast biopsy showed that 13 percent required a subsequent biopsy within two years of having routine FNA procedures performed. In a retrospective study, 150 patients with benign histology after ultrasound-guided vacuum-assisted biopsy for complex cystic breast lesions (BI-RADS 4) were assessed. This subset of patients underwent study in 6 monthly intervals. Of the 104 lesions, none led to the development of malignancy. [4] Routine ultrasound screening in\u00a0Japan was used with\u00a010519 women to evaluate recall criteria.\u00a0Researchers noted a cystic-type breast pattern in 6512 cases. Only one of the patient cases reported malignancy the following year, related to a solid tumor with a cystic component, proven to be a micro-invasive cancer of less than 1 mm. There was no cancer diagnosed in this subset of patients. Most of the study subjects were less than 40 years of age. [18]"}
{"id": "article-21731_27", "title": "Fibrocystic Breast Disease -- Treatment / Management", "content": "Due to the role of estrogen and progesterone treatments, promoting fibrocystic changes in the breast, metformin has been suggested as a treatment method to reduce the excessive cell proliferation caused by associated hormones. [19]", "contents": "Fibrocystic Breast Disease -- Treatment / Management. Due to the role of estrogen and progesterone treatments, promoting fibrocystic changes in the breast, metformin has been suggested as a treatment method to reduce the excessive cell proliferation caused by associated hormones. [19]"}
{"id": "article-21731_28", "title": "Fibrocystic Breast Disease -- Treatment / Management", "content": "For patients presenting with\u00a0mastalgia, the first-line options are lifestyle changes. Other suggestions are the use of a supportive bra, as well as altering the dose of\u00a0hormone replacement therapy regimen. There is no evidence that reducing caffeine improves fibrocystic breast disease or mastalgia. [20] [21] Analgesics such as aspirin and ibuprofen are options. [22]", "contents": "Fibrocystic Breast Disease -- Treatment / Management. For patients presenting with\u00a0mastalgia, the first-line options are lifestyle changes. Other suggestions are the use of a supportive bra, as well as altering the dose of\u00a0hormone replacement therapy regimen. There is no evidence that reducing caffeine improves fibrocystic breast disease or mastalgia. [20] [21] Analgesics such as aspirin and ibuprofen are options. [22]"}
{"id": "article-21731_29", "title": "Fibrocystic Breast Disease -- Treatment / Management", "content": "Researchers have proposed that a deficiency in prostaglandin E and its precursor gamma-linolenic acid (GLA) increase the sensitivity of breasts during\u00a0the luteal phase of the menstrual cycle. GLA is subsequently also the active component of evening primrose oil.", "contents": "Fibrocystic Breast Disease -- Treatment / Management. Researchers have proposed that a deficiency in prostaglandin E and its precursor gamma-linolenic acid (GLA) increase the sensitivity of breasts during\u00a0the luteal phase of the menstrual cycle. GLA is subsequently also the active component of evening primrose oil."}
{"id": "article-21731_30", "title": "Fibrocystic Breast Disease -- Treatment / Management", "content": "Despite not having proven\u00a0efficacy in previous studies, the use of\u00a0evening primrose oil is warranted as supportive measures if pain persists despite treatment and advice. A 3 to 6 month period is the suggested\u00a0timeframe to observe the desired\u00a0effect [23]", "contents": "Fibrocystic Breast Disease -- Treatment / Management. Despite not having proven\u00a0efficacy in previous studies, the use of\u00a0evening primrose oil is warranted as supportive measures if pain persists despite treatment and advice. A 3 to 6 month period is the suggested\u00a0timeframe to observe the desired\u00a0effect [23]"}
{"id": "article-21731_31", "title": "Fibrocystic Breast Disease -- Treatment / Management", "content": "If breast pain is severe for more than six months and disrupts daily activities, other therapies such as tamoxifen, bromocriptine, or danazol\u00a0can be options. Due to the recurrent nature and long duration of these symptoms, several months of treatment is\u00a0necessary.", "contents": "Fibrocystic Breast Disease -- Treatment / Management. If breast pain is severe for more than six months and disrupts daily activities, other therapies such as tamoxifen, bromocriptine, or danazol\u00a0can be options. Due to the recurrent nature and long duration of these symptoms, several months of treatment is\u00a0necessary."}
{"id": "article-21731_32", "title": "Fibrocystic Breast Disease -- Treatment / Management", "content": "Fluid from cysts aspirated for symptomatic relief does not require cytological assessment. This evaluation is reserved for clinically evident lumps that resolve following the FNA procedure or where the cyst fluid appears macroscopically\u00a0bloodstained. Fluid from atypical cysts should have a cytological assessment. [24] Surgery is indicated for cysts that repetitively, despite frequent FNA,\u00a0which have an\u00a0intra-cystic solid appearance on ultrasound or have atypical cells present upon cytopathological evaluation. [25]", "contents": "Fibrocystic Breast Disease -- Treatment / Management. Fluid from cysts aspirated for symptomatic relief does not require cytological assessment. This evaluation is reserved for clinically evident lumps that resolve following the FNA procedure or where the cyst fluid appears macroscopically\u00a0bloodstained. Fluid from atypical cysts should have a cytological assessment. [24] Surgery is indicated for cysts that repetitively, despite frequent FNA,\u00a0which have an\u00a0intra-cystic solid appearance on ultrasound or have atypical cells present upon cytopathological evaluation. [25]"}
{"id": "article-21731_33", "title": "Fibrocystic Breast Disease -- Differential Diagnosis", "content": "Breast lump Breast abscess Fibrocystic changes Fibroadenomas Infections [26] Trauma Fat necrosis Papilloma Phyllodes tumor Breast ectasia [27]", "contents": "Fibrocystic Breast Disease -- Differential Diagnosis. Breast lump Breast abscess Fibrocystic changes Fibroadenomas Infections [26] Trauma Fat necrosis Papilloma Phyllodes tumor Breast ectasia [27]"}
{"id": "article-21731_34", "title": "Fibrocystic Breast Disease -- Pertinent Studies and Ongoing Trials", "content": "Thirty patients with fibrocystic breast disease received a clinical trial of danazol.\u00a0Twenty-three patients had a 5 to 6-month treatment regime. Partial or complete relief of breast pain and nodularity for all patients included in the clinical trial. The researchers found malignancy in one patient following\u00a0three months of therapy. There were limited reported side effects. Recurrence of symptoms occurred after discontinuation of the drug. [28] A study currently being performed in Japan will assess the efficacy and safety of the Xiaoru Sanjie capsule in the treatment of cyclo-mastopathy. The study will be a multicenter, randomized, open controlled clinical study.", "contents": "Fibrocystic Breast Disease -- Pertinent Studies and Ongoing Trials. Thirty patients with fibrocystic breast disease received a clinical trial of danazol.\u00a0Twenty-three patients had a 5 to 6-month treatment regime. Partial or complete relief of breast pain and nodularity for all patients included in the clinical trial. The researchers found malignancy in one patient following\u00a0three months of therapy. There were limited reported side effects. Recurrence of symptoms occurred after discontinuation of the drug. [28] A study currently being performed in Japan will assess the efficacy and safety of the Xiaoru Sanjie capsule in the treatment of cyclo-mastopathy. The study will be a multicenter, randomized, open controlled clinical study."}
{"id": "article-21731_35", "title": "Fibrocystic Breast Disease -- Staging", "content": "There are not specific characterized stages of benign breast disease used as a standard method of diagnosis; however, fibrocystic type breast disease can be proliferative or non-proliferative types. Non-proliferative types are not associated with unexpected cell growth. Common non-proliferative lesions would include:- Periductal fibrosis Nonsclerosing adenosis Cysts Epithelial-related calcifications Mild epithelial hyperplasia Papillary apocrine changes. Non-proliferative lesions are the most common finding in breast cancer screening biopsies, seen in\u00a070%\u00a0of all cases. Proliferative changes include factors such as\u00a0Intraductal hyperplasia, sclerosing adenosis, radial scars, and papillomas.", "contents": "Fibrocystic Breast Disease -- Staging. There are not specific characterized stages of benign breast disease used as a standard method of diagnosis; however, fibrocystic type breast disease can be proliferative or non-proliferative types. Non-proliferative types are not associated with unexpected cell growth. Common non-proliferative lesions would include:- Periductal fibrosis Nonsclerosing adenosis Cysts Epithelial-related calcifications Mild epithelial hyperplasia Papillary apocrine changes. Non-proliferative lesions are the most common finding in breast cancer screening biopsies, seen in\u00a070%\u00a0of all cases. Proliferative changes include factors such as\u00a0Intraductal hyperplasia, sclerosing adenosis, radial scars, and papillomas."}
{"id": "article-21731_36", "title": "Fibrocystic Breast Disease -- Prognosis", "content": "Proliferative type lesions have a 1.3 to 1.9 times increased risk of\u00a0malignancy for both breasts. Any increase in pleomorphic calcifications on mammograms should qualify for a 6-month interval follow-up regime.", "contents": "Fibrocystic Breast Disease -- Prognosis. Proliferative type lesions have a 1.3 to 1.9 times increased risk of\u00a0malignancy for both breasts. Any increase in pleomorphic calcifications on mammograms should qualify for a 6-month interval follow-up regime."}
{"id": "article-21731_37", "title": "Fibrocystic Breast Disease -- Complications", "content": "A random sampling of fibrocystic breast disease will often reveal fibrosis if fibrosis is detected using MR-guided sampling. Discordant results should be considered, with further evaluation warranted. [29]", "contents": "Fibrocystic Breast Disease -- Complications. A random sampling of fibrocystic breast disease will often reveal fibrosis if fibrosis is detected using MR-guided sampling. Discordant results should be considered, with further evaluation warranted. [29]"}
{"id": "article-21731_38", "title": "Fibrocystic Breast Disease -- Deterrence and Patient Education", "content": "Advice to be provided to patients for preventing and treating fibrocystic breast disease includes: Use over-the-counter pain relievers such as acetaminophen or ibuprofen. Apply warm or cool compresses to breasts when most painful. Wear a comfortable, supportive bra. Avoid large amounts of salt or fat in the diet, which some women find can worsen symptoms. Consider\u00a0an oral contraceptive. Check thyroid levels and suggest the use of iodine. Consider vitamin E, evening primrose oil, and B vitamins.", "contents": "Fibrocystic Breast Disease -- Deterrence and Patient Education. Advice to be provided to patients for preventing and treating fibrocystic breast disease includes: Use over-the-counter pain relievers such as acetaminophen or ibuprofen. Apply warm or cool compresses to breasts when most painful. Wear a comfortable, supportive bra. Avoid large amounts of salt or fat in the diet, which some women find can worsen symptoms. Consider\u00a0an oral contraceptive. Check thyroid levels and suggest the use of iodine. Consider vitamin E, evening primrose oil, and B vitamins."}
{"id": "article-21731_39", "title": "Fibrocystic Breast Disease -- Pearls and Other Issues", "content": "A true lateral mammogram can be useful to distinguish benign calcifications from\u00a0malignant calcifications, such as milk of calcium deposits. [30] Diffuse, scattered, similar bilateral findings favor\u00a0a benign result. Focal pain is not a sign of malignancy though ultrasound can serve as a\u00a0reassurance tool for patients. Thermoablation is currently under assessment as a treatment option for\u00a0benign and malignant lesions. The American Society of Breast Surgeons has raised a warning in the\u00a0assessment and has released a statement for the\u00a0use of ablative treatment. The statement concludes that\u00a0ablative techniques are currently investigational and should not be performed in the United States unless part of a\u00a0clinical research trial. [31]", "contents": "Fibrocystic Breast Disease -- Pearls and Other Issues. A true lateral mammogram can be useful to distinguish benign calcifications from\u00a0malignant calcifications, such as milk of calcium deposits. [30] Diffuse, scattered, similar bilateral findings favor\u00a0a benign result. Focal pain is not a sign of malignancy though ultrasound can serve as a\u00a0reassurance tool for patients. Thermoablation is currently under assessment as a treatment option for\u00a0benign and malignant lesions. The American Society of Breast Surgeons has raised a warning in the\u00a0assessment and has released a statement for the\u00a0use of ablative treatment. The statement concludes that\u00a0ablative techniques are currently investigational and should not be performed in the United States unless part of a\u00a0clinical research trial. [31]"}
{"id": "article-21731_40", "title": "Fibrocystic Breast Disease -- Enhancing Healthcare Team Outcomes", "content": "Communicating information about the diagnosis, treatment, and prognosis to patients with breast disease\u00a0is important for all reported cases in a breast clinic. The best means to accomplish this is an interprofessional team consisting of primary care providers, general surgeons, radiologists, pharmacists, and specialty-trained breast care nurses. Concerns of patients included the language of\u00a0physicians, lack of consideration\u00a0for patient autonomy, and promotion of\u00a0decision-making power to patients. [32]", "contents": "Fibrocystic Breast Disease -- Enhancing Healthcare Team Outcomes. Communicating information about the diagnosis, treatment, and prognosis to patients with breast disease\u00a0is important for all reported cases in a breast clinic. The best means to accomplish this is an interprofessional team consisting of primary care providers, general surgeons, radiologists, pharmacists, and specialty-trained breast care nurses. Concerns of patients included the language of\u00a0physicians, lack of consideration\u00a0for patient autonomy, and promotion of\u00a0decision-making power to patients. [32]"}
{"id": "article-21731_41", "title": "Fibrocystic Breast Disease -- Enhancing Healthcare Team Outcomes", "content": "Pharmacists become involved when using medications to treat this condition. They counsel patients, review side effects, check for drug interactions, and stress the importance of compliance. Breast care nurses educate patients about the good prognosis and the importance of close follow-up initially. They can also chart progress in treatment, or lack thereof, and inform the lead clinician of any concerns that may arise. These examples of interprofessional collaboration show how the team approach can improve patient outcomes and minimize adverse events. [Level 5] Image 4 and 5: Interprofessional care factors to consider during clinical evaluation of breast disease, both benign and malignant findings.", "contents": "Fibrocystic Breast Disease -- Enhancing Healthcare Team Outcomes. Pharmacists become involved when using medications to treat this condition. They counsel patients, review side effects, check for drug interactions, and stress the importance of compliance. Breast care nurses educate patients about the good prognosis and the importance of close follow-up initially. They can also chart progress in treatment, or lack thereof, and inform the lead clinician of any concerns that may arise. These examples of interprofessional collaboration show how the team approach can improve patient outcomes and minimize adverse events. [Level 5] Image 4 and 5: Interprofessional care factors to consider during clinical evaluation of breast disease, both benign and malignant findings."}
{"id": "article-21731_42", "title": "Fibrocystic Breast Disease -- Enhancing Healthcare Team Outcomes", "content": "Psychosocial, home, and work environments require a stable structure to ensure both physical and mental wellbeing. Patients diagnosed with fibrocystic breast disease are also associated with fear and uncertainty due to a lack of education regarding their diagnoses. Proper medical interaction and interprofessional coordination and communication are necessary to ensure a holistic patient output.", "contents": "Fibrocystic Breast Disease -- Enhancing Healthcare Team Outcomes. Psychosocial, home, and work environments require a stable structure to ensure both physical and mental wellbeing. Patients diagnosed with fibrocystic breast disease are also associated with fear and uncertainty due to a lack of education regarding their diagnoses. Proper medical interaction and interprofessional coordination and communication are necessary to ensure a holistic patient output."}
{"id": "article-21731_43", "title": "Fibrocystic Breast Disease -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Fibrocystic Breast Disease -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}